Elaine Chen is a reporter who has written for various publications including STAT, The New York Times, and BioRxiv. Her work covers a range of topics including healthcare, business, and scientific research. Elaine has a keen interest in exploring the intersection of health, technology, and society.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Elaine Chen's coverage primarily focuses on healthcare, pharmaceuticals, and to a lesser extent finance. Her articles frequently cite data and press releases. Sources with access to relevant research findings or industry statistics may find success in pitching to her.
Given the prevalence of topics related to obesity, weight-loss drugs, and health research in her articles, Elaine would likely welcome insights from medical professionals specializing in these areas. Additionally, she might be interested in hearing from experts able to provide context around new developments within the pharmaceutical industry.
As Elaine does not have a specific geographic focus mentioned but covers international news across healthcare and finance sectors, she is likely open to receiving pitches from sources located anywhere globally who can offer valuable insights into these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
A new study on real-world prescriptions of Leqembi, the Alzheimer's drug from Eisai and Biogen, suggests there are already stark disparities in the rollout of the new treatment.
Pharma has over $500B in capital for deals, analysts note — with companies like Novo Nordisk, Eli Lilly, and Merck continuing to be open to early-stage deals:
By Elaine Chen May 9, 2024 Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Late-stage results of Cytokinetics’ drug for a rare heart disease suggest it can compete with a similar treatment sold by Bristol Myers Squibb, and can also be dosed more conveniently.
By Elaine Chen May 14, 2024 Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
By: Isabella Cueto, Elaine Chen
By Isabella Cueto and Elaine Chen May 14, 2024 N ovo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver
By Elaine Chen May 15, 2024 Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Eli Lilly reported Thursday that its experimental weekly insulin works as well as daily basal insulin products in two late-stage studies.
Blackstone Life Sciences said yesterday it's committing up to $300 million to launch a new immunology and inflammation-focused company called Uniquity Bio.
By: Elaine Chen
By Elaine Chen May 17, 2024 A s Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results
(833) 317-6278 
